- Record: found
- Abstract: found
- Article: not found
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Gregory J Riely
1 ,
William Pao ,
Duykhanh Pham ,
Allan R Li ,
Naiyer Rizvi ,
Ennapadam S Venkatraman ,
Maureen F Zakowski ,
Mark G Kris ,
Marc Ladanyi ,
Vincent A Miller
Feb 01 2006
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In patients with non-small cell lung cancer (NSCLC), mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity to erlotinib and gefitinib. We undertook this study to explore the relationship between EGFR mutation type and clinical variables, including treatment with gefitinib and erlotinib.